Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 7/20 | 0.44 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30302508 | 1.00 | MAPT (0.59) | MAPTDDB1CRBNEGFRC5AR1 | |
| SCHEMBL30302556 | 0.94 | MAPT (0.60) | MAPTDDB1CRBNEGFRMAPK1 | |
| SCHEMBL22803935 | 0.94 | MAPT (0.60) | MAPTDDB1CRBNEGFRMAPK1 | |
| SCHEMBL30302492 | 0.93 | MAPT (0.69) | MAPTDDB1CRBNEGFRPDGFRB | |
| SCHEMBL22803333 | 0.93 | MAPT (0.69) | MAPTDDB1CRBNEGFRPDGFRB | |
| SCHEMBL22803331 | 0.92 | MAPT (0.57) | MAPTDDB1CRBNEGFRC5AR1 | |
| SCHEMBL30302506 | 0.92 | MAPT (0.57) | MAPTDDB1CRBNEGFRC5AR1 | |
| SCHEMBL22803993 | 0.87 | MAPT (0.70) | MAPTDDB1CRBNPDGFRBIGF1R | |
| SCHEMBL30302542 | 0.87 | MAPT (0.70) | MAPTDDB1CRBNPDGFRBIGF1R | |
| SCHEMBL22803673 | 0.85 | MAPT (0.58) | MAPTDDB1CRBNEGFRC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | MAPT 3503/4885DDB1 114/4885CRBN 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.